We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis.
- Authors
Demolder, Saartje; Schaevers, Veronique; Lagrou, Katrien; De Munter, Paul; Beeckmans, Hanne; Verleden, Geert M.; Godinas, Laurent; Dupont, Lieven J.; Van Bleyenbergh, Pascal; Lorent, Natalie; Vos, Robin
- Abstract
Lung transplant (LTx) recipients are at high risk for COVID-19 related morbidity and mortality. Data regarding pre-exposure prophylaxis (PrEP) with tixagevimab-cilgavimab in this population are scarce. We therefore evaluated COVID-19 breakthrough infections and COVID-19 related complications after PrEP in a retrospective single-center study, including 264 LTx recipients who received PrEP between June 2022 and December 2022, when Omicron BA.5 was the dominant circulating SARS-CoV-2 variant. PrEP was indicated for fully vaccinated patients with poor seroconversion (anti-S <260 BAU/mL). COVID-19 breakthrough infection after PrEP occurred in 11.0% within the first 3 months, increasing to 17.4% within 6 months. Hospitalization rate rose from 27.6% to 52.9% (p = 0.046), while ICU admissions and COVID-19 mortality remained low, respectively occurring in 6.5% and 4.3% of patients with breakthrough infection within 6 months. COVID-19 breakthrough infection and associated hospitalization remained an important problem during the Omicron BA.5 surge in fully vaccinated LTx recipients with deficient seroconversion, despite PrEP with tixagevimab-cilgavimab. However, ICU admissions and COVID-19 mortality were low. Waning of neutralizing effects of PrEP and changing circulating SARS-CoV-2 variants may explain increases in COVID-19 infections and hospitalizations over time after PrEP, highlighting the need for novel, long-term effective PrEP strategies in these high-risk patients.
- Subjects
PRE-exposure prophylaxis; SARS-CoV-2 Omicron variant; LUNG transplantation; SARS-CoV-2; BREAKTHROUGH infections
- Publication
Transplant International, 2024, p1
- ISSN
0934-0874
- Publication type
Article
- DOI
10.3389/ti.2024.12061